MMF and eye disease

Lupus

Volumn 14, Issue SUPPL. 1, 2005, Pages

  Zierhut, Manfred ^a   Stubiger N ^a   Siepmann, K ^a   Deuter, C M E ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Corneal transplantation; Ocular allergy; Ocular pemphigoid; Scleritis; Uveitis

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DAPSONE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ARTICLE; ATOPIC KERATOCONJUNCTIVITIS; CLINICAL TRIAL; DIZZINESS; ECZEMA; EYE DISEASE; EYE INFLAMMATION; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; HAIR LOSS; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; METHEMOGLOBINEMIA; MUCOUS MEMBRANE PEMPHIGOID; NEPHROTOXICITY; PARESTHESIA; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; RASH; RETINA DEGENERATION; SCLERITIS; UVEITIS;

EID: 16244423316     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2119oa     Document Type: Article

References (25)

1. Kumari S, Bhol KC, Simmons RK et al. Identification of ocular cicatricial pemphigoid antibody binding site(s) in human β4 integrin. Invest Ophthalmol Vis Sci 2001; 42: 379-385.
2. Pouliquen Y, Patey A, Foster CS. Drug-induced cicatricial pemphigoid affecting the conjunctiva. Ophthalmology 1986; 93: 775-781.
3. Kreutzer B, Stübiger N, Thiel HJ, Zierhut M. Oculomucocutaneous changes as paraneoplastic syndromes. German J Ophthalmol 1996; 5: 176-181.
4. Foster CS. Cicactricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84: 527-663.
5. Neumann R, Tauber J, Foster CS. Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology 1991; 98: 858-862.
6. Zurdel J, Aboalchamat B, Zierhut M, Stübiger N, Bialasiewicz A, Engelmann K. Erste klinische Erfahrung mit Mycophenolatmofetil bei der immunsuppressiven Therapie des okulären Pemphigoides. Klin Monatsbl Augenheilkl 2001; 218: 222-228.
7. Reis A, Reinhard T, Sundmacher R, Althaus C, Voiculescu A, Kutkuhn B. Mycophenolate mofetil in ocular immunological disorders. A survey of the literature and 3 case reports. Klin Monatsbl Augenheilk 1998; 213: 257-261.
8. Chanaud NP, Vistica BP, Eugui E, Nussenblatt RB, Allison AC, Gery I. Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. Exp Eye Res 1995; 61: 429-434.
9. Gery I, Mochizuki M, Nussenblatt RB. Retinal specific antigens and immunopathogenic processes they provoke. Prog Retinal Res 1986; 5: 75.
10. Caspi RR, Roberge FG, Chan CC et al. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol 1988; 140: 1490-1495.
11. Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 1999; 218: 222-228.
12. Zierhut M, Stübiger N, Aboalchamat W, Landenberger H, Bialasiewicz AA, Engelmann K. Immunsuppressive Therapie mit Mycophenolat Mofetil (CellCept) in der Behandlung der Uveitis. Ophthalmologe 2001; 98: 647-651.
13. Lau CH, Comer M, Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Exp Ophthal 2003; 31: 487-491.
14. Greiner K, Varikkara M, Santiago C, Forrester JV. Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis. Ophthalmologe 2002; 99: 691-694.
15. Uchio E, Miyakawa K, Ikezawa Z, Ohno S. Systemic and local immunological features of atopic dermatitis patients with ocular complications. Br J Ophthalmol 1998; 82: 82-87.
16. Garrity JA, Liesegang TJ. Ocular complications of atopic dermatitis. Can J Ophthalmol 1984; 19: 21-24.
17. Dogru M, Nakagawa N, Tetsumoto K, Katakmi C, Yamamoto M. Ocular surface disease in atopic dermatitis. Jpn J Ophthalmol 1999; 43: 53-57.
18. Lear JT, English JS, Jones P, Smith AG. Retrospective review of the use of azathioprine in severe atopic dermatitis. J Am Acad Dermatol 1996; 35: 642-643.
19. Hoang-Xuan T, Prisant O, Hannouche D, Robin H. Sytemic cyclosporine A in severe atopic keratoconjunctivitis. Ophthalmology 1997; 104: 1300-1305.
20. Neuber K, Schwartz I, Itschert G, Dieck AT. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 2000; 143: 385-391.
21. Reinhard T, Reis A, Böhringer D et al. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial. Graefe's Arch Clin Exp Ophthalmol 2001; 239: 367-372.
22. Mayer K, Reinhard T, Reis A, Voiculescu A, Sundmacher R. Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study. Graefe's Arch Clin Exp Ophthalmol 2003; 241: 1051-1054.
23. Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 1998; 42: 216-222.
24. Lau CH, Comer, Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Experiment Ophthalmol 2003; 31: 487-491.
25. Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Opthalmology 1999; 106: 370-374.